Last update 21 Nov 2024

Adebrelimab

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
+ [2]
Target
Mechanism
PDL1 inhibitors(Programmed death-ligand 1 inhibitors)
Inactive Organization
Drug Highest PhaseApproved
First Approval Date
RegulationSpecial Review Project (CN)
Login to view timeline

External Link

KEGGWikiATCDrug Bank
---

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Extensive stage Small Cell Lung Cancer
CN
28 Feb 2023
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Advanced Hepatocellular CarcinomaPhase 3
CN
28 Oct 2024
Extensive stage Small Cell Lung CancerPhase 3-01 Oct 2024
Non-squamous non-small cell lung cancerPhase 3
CN
29 Mar 2024
Non-squamous non-small cell lung cancerPhase 3
CN
29 Mar 2024
Small Cell Lung CancerPhase 3
CN
20 Jan 2021
Non-small cell lung cancer stage IIIPhase 3
CN
14 Jul 2020
Advanced Lung Non-Small Cell CarcinomaPhase 2--
Hepatocellular CarcinomaPhase 2
CN
-
HER2 mutant non-small cell lung cancerPhase 2--
Advanced Esophageal Squamous Cell CarcinomaPreclinical
CN
01 Nov 2018
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
67
Adebrelimab + EP/EC chemotherapy
(pskvsxtizt) = mddxahtavn jbgzzxxlut (jgmyqfcmlx, 17.2 - NR)
Positive
01 Sep 2024
Phase 3
67
Adebrelimab + EP/EC + TRT
(nyiagggkvp) = ckdnlcbglj cuffosgodw (sundempozk, 17.2 - not reached)
Positive
24 May 2024
Phase 3
28
Adebrelimab + carboplatin + etoposide + thoracic radiotherapy
(yvunzdujfb) = mfluugpoeu wikgscyfaq (mxsvrmhuxh )
Positive
20 Mar 2024
Phase 3
462
(bklbmafrnr) = rbcbuitmlo hxxamlljdj (jgunckhyih, 13.2 - 17.3)
Positive
07 Dec 2023
Placebo
(bklbmafrnr) = hyhpfutcqz hxxamlljdj (jgunckhyih, 11.3 - 13.9)
Phase 1
30
(kbhodqdtbw) = Common treatment-related adverse events were anorexia (32%) and fatigue (16%), without grade 3 or more adverse events. pntxabmcxt (yabxenafcf )
Positive
24 Jul 2023
Phase 2
63
chemotherapy+sequential chest radiotherapy+SHR-1316
(fhmyctkyhd) = lpaqnveyci kxhwtskhce (gjahdbxaug, 4.3 - 9.7)
Positive
26 May 2023
Pubmed
ManualManual
Phase 1
37
(gnoluibbtv) = npjopvsorx tavhhmhsmw (sxzmbvvevy, 35.9 - 66.6)
Positive
30 Sep 2022
Phase 1
41
(lipdmqhswc) = amkncbevnk xqjspufagw (jjrvzonbqi )
Positive
10 Sep 2022
Phase 2
24
(ptulpnubyd) = xeashrajoz qvffknstxi (xtdqslfttw )
Positive
02 Jun 2022
Phase 1
-
SHR-1316+chemotherapy
(fflgfkhlmj) = rshxpupbgf wduhcpymhz (klemknapar, 39.5 - 71.1)
Positive
03 Apr 2022
placebo+chemotherapy
-
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free